Ikonisys Enters Into Research Collaboration, Option Agreement

Ikonisys announced the execution of an agreement that grants Ikonisys exclusive rights to certain reagents for use with the proprietary Celloptics technology platform developed by Ikonisys. The agreement with Cancer Research Technology Limited grants Ikonisys a worldwide exclusive option to commercialize monoclonal antibodies and other reagents specific for the detection of circulating tumor cells in conjunction with the Ikoniscope/IkoniLAN system enabling robotic microscopy.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=232869)